Skip to content

Therapeutic Writing to Reduce Stress

Writing to Reduce Stress in Expectant Moms: The RESet Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03904979
Acronym
RESeT
Enrollment
15
Registered
2019-04-05
Start date
2019-10-22
Completion date
2022-02-17
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Risk Pregnancy, Pregnancy Complications, Stress, Physiological

Brief summary

Purpose: The investigators hypothesize that exposure to chronic environmental stress is a risk factor for adverse pregnancy outcomes related to preterm birth and preeclampsia among high-risk pregnant women. Additionally, the investigators hypothesize that women can be screened for high levels of environmental stress through the perceived stress scale, and therapeutic writing can be used as a low-resource intervention to help decrease maternal perceived stress and inflammation - measured through analysis of maternal serum and placental samples. Participants: Pregnant women at high risk for adverse pregnancy outcomes, including pre-eclampsia and preterm birth, enrolled in prenatal care at UNC will be recruited for participation Procedures: Using results from the perceived stress scale, the investigators will identify women who screen positive for high environmental stress. Women meeting inclusion criteria will be contacted for possible participation at regularly scheduled prenatal visits. Women who are enrolled will be randomized to generalized writing prompts, therapeutic writing prompts, or no writing during their pregnancy to be administered at each prenatal visit. Maternal blood sample for biochemical markers of stress and gene expression will be obtained at the initial visit; a followup blood sample will be obtained later in pregnancy, and a small portion of the placenta saved at delivery. Delivery outcomes will be obtained through medical record review.

Detailed description

During pregnancy, women regularly interact with healthcare professionals, an often untapped resource and opportune time to optimize mental health, positively impacting outcomes. Cumulative psychosocial stress is a risk factor for several adverse obstetric outcomes including preterm birth (PTB), preeclampsia, fetal growth restriction, and postpartum depression. The overarching hypothesis of this study is that pregnant women with high levels of stress can be identified through easily-implemented screening tools; importantly, the investigators propose that these women can be engaged in care via a cost-effective therapeutic writing intervention combined with the availability of expert pastoral and perinatal psychiatry resources. Women will be enrolled early in pregnancy and followed prospectively. Some women (if randomized to a writing group) will complete a standardized writing prompt at several time points during gestation. The investigators will follow their outcomes prospectively.

Interventions

OTHERWriting exercises

Participants will be given journals with writing prompts to be completed throughout their pregnancy.

Sponsors

University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Masking description

Participants will have identical journals regardless of the intervention or control group status, and providers will be blinded to the writing prompts that participants are given. Women who are randomized to 'no writing' will be provided a blank journal without any instruction. this will be considered a 'gift' for study participation

Intervention model description

Randomized Controlled Trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Women will be prospectively recruited. 1. Gestational age: All women presenting for prenatal care at 8.0 to 19.9 weeks' gestation through the UNC-Hospitals High Risk obstetrics clinic will be screened for high risk of an adverse pregnancy outcome (ex: preterm birth or pre-eclampsia) through review of their medical record. 2. Singleton viable intrauterine pregnancy, with dating confirmed by ultrasound or plans for ultrasound to confirm dating prior to study enrollment 3. No structural abnormalities or aneuploidy 4. Ability to communicate in and provide consent in English 5. Women with at least ONE of the following high risk criteria: a. Short cervix by endovaginal ultrasound, measuring \<25mm b. Prior spontaneous preterm birth 16.0 - 33.9 weeks' gestation i. Documentation of the prior spontaneous preterm birth in the patient's medical records is desirable but is not required for eligibility. ii. The previous preterm delivery cannot be an antepartum stillbirth but an intrapartum stillbirth (due to extreme prematurity) is allowable. c. Chronic hypertension on medications d. History of pre-eclampsia requiring delivery \<37 weeks' gestation, or history of severe pre-eclampsia delivering at any gestational age OR 6. Women with at least TWO of the following moderate risk criteria: 1. Prior preterm birth 34.0-36.9 weeks 2. Chronic hypertension not requiring medications 3. History of term pre-eclampsia 4. Type II diabetes on insulin 5. Obesity with a BMI \>30 6. Smoking during pregnancy 7. Black race 8. Maternal age \<18 years old or \>40 years old 9. Nulliparous 10. Uninsured, or medicaid insurance 7. Women who meet at least one major or 2 minor inclusion criteria along with the other criteria above will then be screened for high levels of acute and chronic stress and trauma using the Perceived Stress questionnaire to determine final eligibility for the study

Exclusion criteria

1. Persistent Illicit drug or alcohol abuse during current pregnancy \>12 weeks. Use of tobacco and/or marijuana is not an exclusion. Methadone or suboxone use in an approved treatment program is not an exclusion. 2. Prior preterm birth or preeclampsia was in a pregnancy complicated by fetal aneuploidy or major congenital fetal anomalies in the absence of another pregnancy meeting above inclusion criteria 3. Major congenital anomaly such as major structural deficit of the heart, lungs, or brain or aneuploidy 1. Mild renal abnormalities, clubfoot, isolated cleft lip/palate, etc. in the fetus are not a reason for exclusion 2. For a detailed list of major anomalies, see Table 3 - Major Fetal Anomalies / Congenital Malformations, below. Two or more minor anomalies observed together (see Table 2 - Minor Fetal Anomalies / Congenital Malformations) count as a major anomaly 3. Isolated 'soft markers' for aneuploidy (such as choroid plexus cysts, echogenic bowel, etc.) are not a reason for exclusion 4. If aneuploidy screening is performed, any aneuploidy screen positive test with a risk for aneuploidy greater than 1 in 25 without negative confirmatory definitive aneuploidy testing is reason for exclusion 4. Spanish speaking women 5. Women participating in other intervention-based studies

Design outcomes

Primary

MeasureTime frameDescription
Change in stress-related gene expression in maternal blood by outcomethrough study completion, an average of 7 months per participant and 2 years for entire studyAll women participating in the study will have a blood draw. We will evaluate gene expression of the CTRA gene panel (conserved transcriptional response to adversity gene panel) by whether or not the patient developed the adverse perinatal outcome
Percent Participation in Writing Activitythrough study completion, an average of 7 months per participant and 2 years for entire studyThe percentage of women who respond that they completed their assigned writing activity will be measured.
Statistically significant improvement (reduction) in the Perceived Stress Scale Scorethrough study completion, an average of 7 months per participant and 2 years for entire studyPsychological instrument used to measure one's perception of stress (score range 0-40) will be assessed before and after the assigned writing activity. Higher scores on the scale indicate a higher vulnerability for those with a high levels of perceived stress in their life. Prior studies have noted the average score for a female age 30-44 is approximately 14.
Proportion of women with adverse perinatal outcomesoutcome will be ascertained at deliveryWe will define adverse pregnancy outcomes as a composite of preterm birth \<37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
Change in pro-inflammatory biomarkers in maternal blood by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studyAll women participating in the study will have a blood draw. Levels of stress biomarkers (e.g., interleukin-6) will be compared by randomization group
Change in pro-inflammatory biomarkers in maternal blood by outcomethrough study completion, an average of 7 months per participant and 2 years for entire studyAll women participating in the study will have a blood draw. Levels of stress biomarkers (e.g., interleukin-6) will be compared between women who develop the adverse perinatal outcome and those who do not
Change in stress-related gene expression in maternal blood by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studyAll women participating in the study will have a blood draw. We will evaluate gene expression of the CTRA gene panel (conserved transcriptional response to adversity gene panel) by randomization group

Secondary

MeasureTime frameDescription
Utilization of professional psychiatric carethrough study completion, an average of 7 months per participant and 2 years for entire studyproportion of women who initiate or continue therapy with professional psychiatric care provider
Stress related pathways gene expression - placental tissue - by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studyAfter delivery, we will evaluate whether there are differences in the conserved transcriptional response to adversity gene panel (CTRA gene panel) by randomization groups
Stress related pathways gene expression - placental tissue - by diagnosis of adverse perinatal outcomethrough study completion, an average of 7 months per participant and 2 years for entire studyAfter delivery, we will evaluate whether there are differences in the conserved transcriptional response to adversity gene panel (CTRA gene panel) by whether or not the patient developed the adverse perinatal outcome
Rate of preterm birth less than 37 weeks' gestation by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studywe will individually evaluate the outcomes of preterm birth \<37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
Rate of diagnosis of intrauterine growth restriction, using sex-specific curves, by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studywe will individually evaluate the outcomes of preterm birth \<37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
Rate of diagnosis of preeclampsia by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studywe will individually evaluate the outcomes of preterm birth \<37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups
Rate of diagnosis of placental abruption by randomization groupthrough study completion, an average of 7 months per participant and 2 years for entire studywe will individually evaluate the outcomes of preterm birth \<37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026